Why the study?
Clinical trials found differences in bleeding locations between DOAC and VKA, but real-life data from adverse drug reaction reports were needed to further investigate these differences.
Do direct oral anticoagulants alter the location of bleeding events compared to vitamin K antagonists in adults?
Do direct oral anticoagulants alter the location of bleeding events compared to vitamin K antagonists in adults?
Real-world pharmacovigilance data reveals that DOACs are associated with less cerebral, urologic, and nasal bleeding but more gynaecologic bleeding compared to VKAs.
Answers are grounded in this paper and cite their sources.
Observed bleeding site differences with DOACs versus VKAs need prospective confirmation; leaves open effects on individualized selection.
AIMS: Clinical trials have found differences in bleeding locations between direct oral anticoagulants (DOAC) and vitamin K antagonists (VKA). The present study was performed to investigate these differences in real life using reports of adverse drug reactions registered in the World Health Organization's pharmacovigilance database, VigiBase®. METHODS: All bleeding registered between 1 January 2008 and 31 December 2021 in adults were included. The main objective was to compare bleeding locations reported with DOAC with those with VKA. As a secondary objective, we performed the same comparison with Xa vs. thrombin inhibitors. Results were presented as reporting odds ratios (RORs) adjusted on age, gender, origin of reports and co-medications with their 95% confidence interval. RESULTS: During this 14-year period, 142 228 instances of bleeding were registered with oral anticoagulants, including 39 570 with VKA and 102 658 with DOAC. Mean time to event was lower with DOAC (7.6 months) than with VKA (29.9 months) (P < .001). Significant differences in bleeding locations were found in the reports with less cerebral, urologic and nasal bleeding, more gynaecologic bleeding with DOAC than with VKA, without any significant differences in digestive and cutaneous locations. A higher risk of bleeding reports was found with Xa inhibitors vs. dabigatran whatever the locations (except digestive bleeding). CONCLUSION: This real-life study shows that the differences in bleeding locations between DOAC and VKA are not limited to the brain or gastrointestinal tracts. Significant differences were also found between Xa and thrombin inhibitors.
No takes yet. Share an insight, caveat, or question.
Montastruc et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: